On the morning of October 25, the AstraZeneca Global R&D Beijing Center Innovation Ecosystem Forum was held in the Beijing Economic-Technological Development Area (BDA). Yin Yong, Deputy Secretary of the CPC Beijing Municipal Committee and Mayor of Beijing, attended and addressedthe event.
Yin Yong stated that the pharmaceutical and health industry is a strategic emerging sector vital to public health and well-being as well as high-quality economic development. With rich scientific and medical resources, Beijing possesses distinct strengths in developing the pharmaceutical and health industry, supported by innovation entities with nationwide influence, medical institutions serving the whole country, talent teams exerting broad impact, and open platforms setting national benchmarks. In recent years, Beijing has successively implemented several rounds of three-year action plans for collaborative innovation in the pharmaceutical and health sector, aiming to build an industry cluster with global influence. We have focused on ensuring comprehensive factor support by establishing dedicated industrial funds for pharmaceuticals and health,and developing the Bio-Park. A convenient service system has been fostered to support the centralized presence in Beijing of regulatory authoritiessuch as the Center for Drug Evaluation of National Medical Products Administration. We have also fostered an open and innovative ecosystem by taking the lead in piloting greater openness in the healthcare sector and strengthening support measures in intellectual property protection and other areas. Several leading multinational pharmaceutical companies have newly established R&D or innovation entities in Beijing. The unveiling of the AstraZeneca Global R&D Beijing Center signifies AstraZeneca’s deeper integration into Beijing’s innovation-driven pharmaceutical and health ecosystem. Efforts will continue to be made to foster a market-oriented, law-based, and accessible business environment in keeping with international standards, providing greater development opportunities for global pharmaceutical enterprises. All partners are encouraged to further engage in Beijing, participate in the city’s pharmaceutical and health industry development, and share opportunities and shape the future together.
Pascal Soriot, Chief Executive Officer of AstraZeneca, delivered remarks at the event. The ceremony also featured the unveiling of the AstraZeneca Global R&D Beijing Center, the signing of the Beijing–Cambridge Ecosystem Project, and the inauguration of the Harbour BioMed–AstraZeneca Innovation Lab.
Jin Wei, Member of the Standing Committee of the CPC Beijing Municipal Committee and Vice Mayor of Beijing, Zeng Jin, Secretary General of the People’s Government of Beijing Municipality, Peter Wilson, British Ambassador to China, and Per Augustsson, Sweden’s Ambassador to China, attended the event.
